Meta Pixel

News and Announcements

Mastering the Art of Raising Capital: Patience, Diligence, and the Journey to Venture Capital Success

  • Published April 16, 2023 11:00PM UTC
  • Publisher Jade Miguel
  • Categories Capital Raising Tips

As founders, we often approach our ventures with impatience, optimism, and confidence. However, the reality of raising capital can be a harsh wake-up call.

Initially, we envision investors eagerly investing in our amazing business or idea. After all, we are our own biggest fans, having invested significant time and energy into our projects. However, the capital raising process often exposes the flaws in our businesses, leading to a continuous cycle of rejection. Some founders may start to self-destruct or blame others for their inability to secure venture capital.

The truth is, raising capital is rarely a quick process. It requires patience, diligence, and a methodological approach. Sometimes, investors may only decide to invest after several years of knowing about your business. They wait for specific milestones that move them from being fence-sitters to committed investors.

However, there are instances where investors commit after just one phone call. This is often due to years of hard work, dedication, visibility, strategic communication, and an investor-friendly capital-raising process aligning with their investment thesis.

It’s essential to remember that 90% to 99% of investors may not be interested in your business. Your goal is to find the 1 to 10% who will. To succeed in raising capital, consider these six principles:

  1. Be diligent and persistent in your capital raising efforts.
  2. Maintain visibility and create your own serendipity.
  3. Aim to attract 50 investors to your deal room within the first two months.
  4. Communicate with potential investors 4 to 12 times per year.
  5. Understand that more people are watching your progress than you may
Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now